Skip to main content

Table 5 Predictors of overall survival

From: Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study

Characteristic Univariate Multivariate
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age (per year) 0.990 0.952-1.029 0.601    
Gender (male vs. female) 0.778 0.269-2.246 0.641    
Liver cirrhosis (with vs. without) 1.011 0.430-2.377 0.980    
Child-Pugh class (A vs.B) 0.245 0.090-0.668 0.003 0.436 0.155-1.226 0.116
Main portal trunk invasion (with vs. without) 2.079 1.019-4.243 0.040 2.099 0.941-4.682 0.070
Node metastasis (with vs. without) 0.732 0.350-1.531 0.405    
Baseline tumor size (per 1 cm) 0.912 0.830-1.002 0.056    
Baseline AFP (per 100 ng/mL) 1.000 0.998-1.003 0.711    
Baseline DCP (per 100 mAU/mL) 1.001 0.999-1.002 0.256    
Radiation dose (per 100 cGy) 1.007 0.943-1.074 0.843    
Objective response after CCRT (with vs. without) 0.096 0.036-0.254 <0.001 0.028 0.005-0.148 <0.001
AFP after CCRT (per 100 ng/mL) 1.000 0.998-1.003 0.702    
DCP after CCRT (per 100 mAU/mL) 1.003 1.001-1.004 0.001    
Additional TACE (with vs. without) 0.296 0.137-0.641 0.001 0.134 0.047-0.383 <0.001
Round of HAIC 0.805 0708-0.915 0.001 0.742 0.626-0.880 0.001
  1. AFP α-fetoprotein, DCP Des-gamma carboxyprothrombin, CCRT Concurrent chemoradiation therapy, TACE Transarterial chemoembolization, HAIC Hepatic arterial infusional chemotherapy